Related Experiment Video
Updated: Oct 18, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension
Bertram Pitt1, Frederic Jaisser2, George Bakris3
1Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA.
Insights
Resistant hypertension in advanced chronic kidney disease (CKD) poses risks. A new non-steroidal MRA, KBP-5074, shows promise for treating this condition without causing hyperkalemia.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Resistant hypertension (RH) is common in advanced chronic kidney disease (CKD), increasing cardiovascular and renal risks.
- Current steroidal mineralocorticoid receptor antagonists (MRAs) are limited by hyperkalemia risk in CKD patients.
- KBP-5074 is a novel non-steroidal MRA designed to treat RH in CKD without hyperkalemia.
Purpose of the Study:
- To review current RH treatment in stage 3B/4 CKD.
- To explore limitations of steroidal MRAs.
- To evaluate the potential of KBP-5074 in this patient population.
Main Methods:
- Overview of steroidal MRA limitations in CKD.
- Exploration of emerging data on non-steroidal MRAs.
- Focus on KBP-5074's applicability.
Main Results:
- KBP-5074 demonstrated clinical efficacy in a Phase 2b trial.
- The novel non-steroidal MRA was safe for treating RH in stage 3B/4 CKD.
- No hyperkalemia-related adverse events were reported.
Conclusions:
- KBP-5074 offers a potential new treatment for RH in stage 3B/4 CKD.
- This non-steroidal MRA may improve outcomes in patients at high risk for CVD and CKD progression.
- KBP-5074 addresses an unmet need for safe and effective RH treatment in CKD.
Introduction:
Resistant hypertension (RH) is more prevalent in the advanced stages of chronic kidney disease (CKD) and contributes to a greater likelihood of poor cardiovascular and renal outcomes. However, RH often goes untreated in this population as the currently available recommended add-on therapy, steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, may lead to unacceptable side effects, mainly hyperkalemia in a cohort with reduced kidney function. KBP-5074 is a novel non-steroidal MRA that addresses the unmet need of treating RH in the CKD population without hyperkalemia.
Areas Covered:
We provide an overview of the current state of RH treatment in stage 3B/4 CKD as it relates to available steroidal MRAs and the current limitations of this treatment. We then explore the emerging data on nonsteroidal MRAs, particularly the novel agent KBP-5074 and its applicability to treatment in this context.
Expert Opinion:
In a randomized, double-blind, placebo-controlled phase 2b trial, the novel nonsteroidal MRA KBP-5074 demonstrated clinical efficacy and safety in treating RH in stage 3B/4 CKD and offers a potential new treatment option in this population at high risk for cardiovascular disease (CVD) and CKD progression.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention

